Aleutian Therapeutics, Inc.
Publicly observedLos Angeles, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Los Angeles | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Aleutian Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | E797SLBJB9F1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant7 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy
USD 372,067.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant18 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of a gene edited platform to enable human allogeneic cell replacement therapy
USD 305,855.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 May 2025Publicly observed
NIH SBIR/STTR award: Development of immune evasive strategies for allogeneic cell replacement therapies
USD 307,091.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.